mDR Limited Seeks Extension for SGX Waiver Amid Ongoing CMS Licence Application

Key Highlights

• mDR Limited is requesting an extension from the Singapore Exchange (SGX-ST) for a waiver under Rule 1020 of the SGX Listing Manual.
• The initial waiver was granted for a period of one year, effective from 16 April 2025 to 15 April 2026.
• The company is still in the process of obtaining a Capital Markets Services (CMS) Licence from the Monetary Authority of Singapore (MAS).
• The outcome of the waiver extension and CMS Licence application may have a material impact on the Company’s business direction and compliance status.

Details and Implications for Shareholders

mDR Limited (Incorporated in Singapore, Company Registration No. 200009059G) has provided an important update for its shareholders regarding its regulatory status. The company previously announced, on 16 April 2025, the receipt of a waiver from the Singapore Exchange Securities Trading Limited (SGX-ST) concerning Rule 1020 of the Listing Manual. This waiver was valid for one year and is set to expire on 15 April 2026.

As that expiry date approaches, mDR Limited has formally sought an extension of the waiver from SGX-ST. The company emphasized that this request is necessary because it is still in the midst of securing a Capital Markets Services (CMS) Licence from the Monetary Authority of Singapore (MAS). The CMS Licence is a significant regulatory requirement for the group’s current and future business activities in the financial sector.

Shareholders should note that the successful extension of this waiver is critical for the company’s ongoing compliance with SGX Listing Rules. If the waiver is not extended and the CMS Licence is not granted in time, there could be regulatory and operational implications for mDR Limited, potentially affecting its business continuity, strategic initiatives, and share price.

The company has stated that it will provide further announcements as soon as there are material developments regarding both the waiver extension and the CMS Licence application. In the meantime, shareholders and potential investors are advised to monitor company updates closely and to consult their professional advisers if they have any uncertainties regarding this matter.

Potential Price-Sensitive Information

• The outcome of the waiver extension and CMS Licence application could significantly influence mDR Limited’s business prospects and market valuation.
• Regulatory uncertainty may create volatility or impact investor confidence in the near term.
• Any announcement regarding approval or rejection of either the waiver extension or the CMS Licence could result in material movement in share price.

Next Steps

mDR Limited will continue to engage with the SGX-ST and MAS, and will keep shareholders updated on any developments. Investors are strongly encouraged to stay informed by reviewing all future announcements from the company.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with their professional advisers before making any investment decisions. The author and publisher accept no liability for any losses incurred as a result of reliance on the information provided.

View MDR Limited Historical chart here